Digoxin Antibody (103): sc-57080

Digoxin Antibody (103) is a mouse monoclonal IgG1 antibody that detects Digoxin with species reactivity specific to Digoxin, and is suitable for use in enzyme-linked immunosorbent assay (ELISA) applications. Digoxin, a potent cardiac glycoside, plays a crucial role in the management of heart conditions by decreasing the conduction of electrical impulses through the atrioventricular (AV) node and enhancing the force of heart contractions. This is achieved through binding to and inhibition of the Na+/K+ ATPase pump, which results in an increase in intracellular sodium levels in myocytes, subsequently leading to elevated calcium ion concentrations. The importance of this mechanism cannot be overstated, as Digoxin directly contributes to improved cardiac output in patients suffering from congestive heart failure and other cardiac dysrhythmias. Extracted from the foxglove plant, known scientifically as Digitalis, Digoxin has been utilized in clinical settings to stabilize atrial fibrillation and atrial flutter, while also normalizing abnormal heart rhythms. With a half-life of approximately 36 hours, effective plasma levels of Digoxin range from 1 to 2.6 nmol/l, making Digoxin a vital therapeutic agent in cardiology. anti-Digoxin antibody (103) is an essential tool for researchers and clinicians seeking to explore the therapeutic effects and mechanisms of this important cardiac glycoside.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Digoxin Antibody (103) References:

1. Digoxin: placental transfer, effects on the fetus, and therapeutic use in the newborn.  |  Soyka, LF. 1975. Clin Perinatol. 2: 23-35. PMID: 1102216
2. Digoxin toxicity in the aged. Characterising and avoiding the problem.  |  Passmore, AP. and Johnston, GD. 1991. Drugs Aging. 1: 364-79. PMID: 1794026
3. A perspective on re-evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile.  |  Adams, KF., et al. 2014. Eur J Heart Fail. 16: 483-93. PMID: 24574198
4. Digoxin--a redundant drug in congestive cardiac failure.  |  Poole-Wilson, PA. and Robinson, K. 1989. Cardiovasc Drugs Ther. 2: 733-41. PMID: 2488085
5. Digoxin targets low density lipoprotein receptor-related protein 4 and protects against osteoarthritis.  |  Wang, KD., et al. 2022. Ann Rheum Dis. 81: 544-555. PMID: 34853001
6. Digoxin protects against intervertebral disc degeneration via TNF/NF-κB and LRP4 signaling.  |  Meng, Q., et al. 2023. Front Immunol. 14: 1251517. PMID: 37790932
7. Expert Consensus on the Diagnosis and Management of Digoxin Toxicity.  |  Hack, JB., et al. 2025. Am J Med. 138: 25-33.e14. PMID: 39265879
8. Serum digoxin concentrations in atrial fibrillation: a review.  |  Masuhara, JE. and Lalonde, RL. 1982. Drug Intell Clin Pharm. 16: 543-6. PMID: 7049644
9. [Digoxin and angiotensin-converting enzyme inhibitors in the treatment of chronic congestive heart failure].  |  Thery, C. 1994. Therapie. 49: 211-8. PMID: 7878586
10. Is there an expanded role for digoxin in patients with heart failure and sinus rhythm? A protagonist viewpoint.  |  Williamson, KM. and Patterson, JH. 1997. Ann Pharmacother. 31: 888-92. PMID: 9220052

The preferred Digoxin antibody is Digoxin Antibody (102): sc-57079.